Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.74 USD | -5.60% | +0.84% | -2.63% |
12:23pm | Phio Pharmaceuticals Files $100 Million Mixed Shelf | MT |
May. 15 | Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 75M | Capitalization | 3.6M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | 47M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.05 x |
P/E ratio 2024 * |
-0.43
x | P/E ratio 2025 * |
0.21
x | Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
1 day | -0.38% | ||
1 week | +13.25% | ||
Current month | +12.79% | ||
1 month | +22.50% | ||
3 months | +3.14% | ||
6 months | -23.15% | ||
Current year | +3.14% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 17-09-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 12-06-18 |
Director/Board Member | 73 | 22-05-01 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 13-04-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 0.74 | -5.60% | 69 515 |
24-05-20 | 0.7839 | -0.38% | 247,642 |
24-05-17 | 0.7869 | +7.44% | 278,259 |
24-05-16 | 0.7324 | -8.45% | 90,462 |
24-05-15 | 0.8 | +9.02% | 104,844 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.14% | 3.6M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+47.58% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- PHIO Stock